InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,346.56
(
-1.84%
)
US TECH 100
17,900.00
(
-2.65%
)
Dow Jones
39,737.26
(
-1.51%
)
Brent Oil
77.36
(
0.00%
)
Bitcoin
60,192.71
(
-2.00%
)
Post# of 252778
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: None

Monday, 04/22/2013 8:48:54 AM

Monday, April 22, 2013 8:48:54 AM

Post# of 252778
Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy). Analyst Chad Messer is positive on eteplirsen and says he believes "the market reacted inappropriately to last week's regulatory update." The FDA requested "additional information" last Monday in order to evaluate an Accelerated Approval application, news the market did not like
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up